The announcement of the termination of the clinical trials of suvodirsen came after the Phase 1 open-label extension (OLE) study. The trials showed no positive changes in the expression of the dystrophin from the baseline. Thus, the company has decided to halt the two trials, the OLE study and Phase II/III DYSTANCE 51 trial. The news led to the plunging of the stocks of Wave Life Sciences losing 53.7% t 12:56 p.m. EST on Monday as revealed by NASDAQ. On the contrary, its rival Sarepta Therapeutics has shocked the Pharmaceutical market on receiving surprising FDA-approval for its Duchenne Muscular Dystrophy drug Vyondys 53. Vyondys 53 had failed to gain FDA nod three months back when the company first filed for its approval in light of safety concerns it caused.